Publications by authors named "S Lariven"
We show the value of real-time data generated by a computerized decision support system in primary care in strengthening pneumonia surveillance. The system showed a 66% (95% CI 64%-67%) increase in community-acquired pneumonia from 2018 to 2023 for the population of France, 1 month before a national alert was issued.
View Article and Find Full Text PDFBackground: Suboptimal use of antimicrobials is a driver of antimicrobial resistance in West Africa. Clinical decision support systems (CDSSs) can facilitate access to updated and reliable recommendations.
Objective: This study aimed to assess contextual factors that could facilitate the implementation of a CDSS for antimicrobial prescribing in West Africa and Central Africa and to identify tailored implementation strategies.
Article Synopsis
- The study examines how computerised decision-support systems (CDSS) impact antibiotic prescribing practices among primary care physicians in France, focusing on their appropriate usage.
- Data was collected from over 60,000 registered physicians on a CDSS, revealing that the median appropriateness of antibiotic prescriptions was 77.8%, with 10% of doctors scoring below 50%.
- Key factors influencing appropriate prescribing included prior use of the CDSS, being a general practitioner, working in primary care, mentoring students, and age, suggesting that CDSS may enhance antibiotic prescribing practices.
Background: Respiratory syncytial virus (RSV) is widely recognized as a cause of acute respiratory failure in infants and immunocompromised patients. However, RSV can also contribute to acute respiratory failure in adults, particularly among the elderly population. The objective of this study was to analyze the clinical characteristics and outcomes of immunocompetent adults hospitalized for RSV infection.
View Article and Find Full Text PDFWe evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.
View Article and Find Full Text PDF